Drug Information

Drug General Information
Drug ID
D0M7OU
Former ID
DNC000474
Drug Name
CP-461
Drug Type
Small molecular drug
Indication Inflammatory bowel disease [ICD9: 555, 556; ICD10:K50, K51] Phase 2 [521555]
Structure
Download
2D MOL

3D MOL
Formula
C25H22ClFN2O
Canonical SMILES
CC1=C(C2=C(C1=CC3=CC=NC=C3)C=CC(=C2)F)CC(=O)NCC4=CC=CC=<br />C4.Cl
InChI
1S/C25H21FN2O.ClH/c1-17-22(13-18-9-11-27-12-10-18)21-8-7-20(26)14-24(21)23(17)15-25(29)28-16-19-5-3-2-4-6-19;/h2-14H,15-16H2,1H3,(H,28,29);1H/b22-13-;
InChIKey
KGXPDNOBLLACKL-BWLGBDCWSA-N
CAS Number
CAS 279238-68-5
PubChem Compound ID
6445781
PubChem Substance ID
11969898, 14929435, 43037926, 50069163, 57369867, 76715519, 80916249, 114573624, 134339890, 135142222, 198959721
Target and Pathway
Target(s) CGMP-dependent3',5'-cyclic phosphodiesterase Target Info Inhibitor [535265]
KEGG Pathway Purine metabolism
cGMP-PKG signaling pathway
Morphine addiction
NetPath Pathway TSH Signaling Pathway
Reactome cGMP effects
G alpha (s) signalling events
References
Ref 521555ClinicalTrials.gov (NCT00060710) CP-461 in the Treatment of Patients With Advanced Melanoma. U.S. National Institutes of Health.
Ref 535265Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs. 2001 May;2(5):677-83.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.